The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.

In Vivo briefly summarizes the technologies of these recently founded companies: Ansata Inc., BioRexis Pharmaceutical Corp., Dentigenix LLC, DermaCo Inc., PhysioGenix Inc. and Zivena Inc.